Johns Hopkins Researchers Uncover Genes at Fault for Cystic Fibrosis-Related Intestinal Obstruction - 04/23/2012
Johns Hopkins Researchers Uncover Genes at Fault for Cystic Fibrosis-Related Intestinal Obstruction
Researchers at Johns Hopkins have identified a gene that modifies the risk of newborns with cystic fibrosis (CF) developing neonatal intestinal obstruction, a potentially lethal complication of CF. Their findings, which appeared online March 15 in PlosGenetics, along with the findings of their Toronto-based colleagues, published April 1 in Nature Genetics, may lead to a better understanding of how the intestines work and pave the way for identifying genes involved in secondary complications of other disorders.
Soon after birth, most babies excrete their first stool, a tar-like substance called meconium. But not babies with neonatal intestinal obstruction, or meconium ileus (MI), which affects 15 percent of newborns with CF and, rarely, newborns without CF. Their stool is different.
“It is abnormally viscous due to high protein content and low levels of hydration, and the child can't move it through the intestine,” says Garry Cutting, M.D., professor of pediatrics at the Johns Hopkins McKusick-Nathans Institute of Genetic Medicine.
The condition results in death if not treated by surgery or enema. But why some newborns with CF get it and others don’t is not well understood. To better understand why this is so and to develop models for finding so-called modifier genes—genes that modify the effects of other genes—Cutting and his colleagues aimed to figure out which modifier genes contribute to the development of MI. (From their previous work, they already knew that modifier genes contribute to its development.)
Working with Toronto-based collaborators, members of Cutting’s team looked for gene variants that occur in CF patients with MI. They knew that CF is caused by disruption of the CFTR gene, which encodes for a cell membrane protein, so they thought that maybe the genes that alter CFTR’s activity and cause MI might also encode for cell membrane proteins; after all, a cell membrane protein is more likely to interact with a nearby cell membrane protein than with a protein that’s deep inside the cell. They tested DNA samples from 3,763 CF patients—611 who had had MI and 3152 who hadn’t—to compare genes that encode for cell membrane proteins to those that encode for unrelated proteins. Three of the 155 genes tested that encode for cell membrane proteins correlated with risk for MI, compared with none of the 231 genes tested that encode for unrelated proteins.
“These genes have common variants that all of us happen to be carrying around,” says Cutting, “and just by chance, if you have a child with CF, these common variants play a role in modifying risk for meconium ileus.”
The researchers wanted to look for additional gene variants associated with an increased risk for MI, using a different approach.
In an earlier study, Cutting’s team had found a region of human chromosome 8 to be linked to MI. To pinpoint which gene within that region leads to the condition, the researchers analyzed the DNA of 133 families with at least two CF children, at least one of whom previously had MI. The DNA was tested to determine which parts of chromosome 8 parents had passed down to their children who had MI. Using this approach, the researchers found variants of the methionine sulfoxide reductase (MSRA) gene—in this case, a particular combination of DNA alterations close to and within the gene—that appeared significantly more often in children who had MI. In an unrelated CF patient population from Canada, they found evidence of the same link between MSRA and MI, which helped confirm their results.
While the researchers now knew that CF patients with a certain MSRA gene variant tended to have had MI as newborns, they didn’t yet know whether MSRA actually plays a role in MI and hence whether it is truly a modifier gene. To address this question, they turned to mice engineered to have CF that tend to die from intestinal obstruction and developed three genetically modified versions of these mice: one with both MSRA genes intact, one with only one intact, and one with none intact. The fewer the copies of intact MSRA genes, the more likely the mice were to survive. In other words, the loss of MSRA protected the mice from fatal intestinal obstruction.
Cutting and his colleagues don’t know how exactly the loss of MSRA reduces risk for fatal intestinal obstruction, but they suspect that MSRA’s ability to alter the activity of specific intestinal enzymes may be the key. They suspect that with reduced levels of MSRA, the enzymes are free to do their job breaking down proteins that make up meconium so that meconium can pass through the intestines and be evacuated normally at birth.
The researchers’ work on MSRA could shed light on how meconium normally gets broken down in the intestines. Moreover, use of the techniques pioneered by Cutting and his colleagues may lead to identification of modifier genes that play roles in other complications of CF, like lung function, and in other diseases caused by a single gene, like Huntington’s disease.
The studies were funded by the National Institutes of Health (NHLBI and NIDDK) and the Cystic Fibrosis Foundation.
Authors on the Plos Genetics paper are: Lindsay B. Henderson, Vishal K. Doshi, Scott M. Blackman, Kathleen M. Naughton, and Garry R. Cutting of Johns Hopkins; Rhonda G. Pace and Michael R. Knowles of University of North Carolina at Chapel Hill; Jackob Moskovitz of University of Kansas, Lawrence; Peter R. Durie of Hospital for Sick Children, Toronto, Ontario, Canada; and Mitchell L. Drumm of Case Western Reserve University.
Authors on the Nature Genetics paper are: Lei Sun, Johanna Rommens, Weili Li, Peter R Durie, Lisa Strug of University of Toronto, Toronto, Ontario, Canada; Harriet Corvol, Annick Clement and Pierre-Yves Boëlle of Pierre et Marie Curie University, Paris, France ; Xin Li, Theodore Chiang, Fan Lin, Ruslan Dorfman, Rashmi V Parekh, Mary Corey, Julian Zielenski of the Hospital for Sick Children, Toronto, Ontario, Canada; Pierre-François Busson of St Antoine Hospital, Paris, France; Diana Zelenika of Centre National de Génotypage, Evry, France ; Scott Blackman, Vishal Doshi, Lindsay Henderson, Kathleen Naughton and Garry R Cutting of Johns Hopkins; Wanda K O'Neal, Rhonda G Pace, Jaclyn R Stonebraker, Sally D Wood and Fred A Wright, and Michael R. Knowles of University of North Carolina at Chapel Hill; and Mitchell L. Drumm of Case Western Reserve University.
Doctor, How Sick Will I Get? It's All In The Genes
On the Web: